Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06586697
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-05-06
Brief Title:
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1PD-L1 Inhibitor Sequential Thoracic Radiotherapy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Sequential Thoracic Radiotherapy for Extensive-stage Small-cell Lung Cancer Treated with Chemo-immunotherapy Followed by PD-1PD-L1 Inhibitor Maintenance Therapya Phase II Single Arm Prospective Trial
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label single arm Phase II study designed to observe and evaluate the efficacy and safety of sequential thoracic radiotherapy in the first-line treatment of extensive small cell lung cancer with chemotherapy combined with approved PD-1PD-L1 inhibitors
Detailed Description:
This study a single arm prospective phase II study All the enrolled patients will be patients with ES-SCLC who did not have PD after 4-6 cycle of platinum-based chemotherapy in combination with an PD-1PD-L1 inhibitors Then those enrolled patients would be treated with thoracic radiotherapy concurrently with PD-1PD-L1 maintenance therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None